ADA updates recommendation for Lilly’s type 2 diabetes drug

The American Diabetes Association  (ADA) has included new recommendation about the use of Jardiance tablets for type 2 diabetes patients to reduce the hearth faliure death risk, Eli Lilly said on Friday.

In 2017  Standards of Medical Care in Diabetes Journal, the ADA updated recommendations that reinforce the critical connection between type 2 diabetes and the increased risk of death due to cardiovascular disease.

Jardiance, marketed by Boehringer Ingelheimand Eli Lilly, is the first and only type 2 diabetes treatment approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of cardiovascular death in adults with type 2 diabetes.